keyword
MENU ▼
Read by QxMD icon Read
search

Remicade and long term effects

keyword
https://www.readbyqxmd.com/read/29205444/switching-from-infliximab-innovator-to-biosimilar-in-patients-with-inflammatory-bowel-disease-a-12-month-multicentre-observational-prospective-cohort-study
#1
E M H Schmitz, P J Boekema, J W A Straathof, D C van Renswouw, L Brunsveld, V Scharnhorst, M E C van de Poll, M A C Broeren, L J J Derijks
BACKGROUND: Infliximab biosimilars have become available for treatment of inflammatory bowel disease (IBD). However, data showing long-term safety and effectiveness of biosimilars in IBD patients are limited. AIM: To study prospectively the switch from infliximab innovator to biosimilar in an IBD cohort with 12 months follow-up to evaluate safety and effectiveness. METHODS: Adult IBD patients from two hospitals treated with infliximab innovator (Remicade; Janssen Biotech,  Horsham ,  Pennsylvania, USA) were switched to infliximab biosimilar (Inflectra; Hospira, Lake Forest, Illinois, USA) as part of routine care, but in a controlled setting...
February 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/24011995/infliximab-for-the-treatment-of-refractory-noninfectious-uveitis-a-study-of-88-patients-with-long-term-follow-up
#2
Jonathan N Kruh, Paul Yang, Ana M Suelves, C Stephen Foster
OBJECTIVE: To establish the safety and efficacy of infliximab for the treatment of refractory noninfectious uveitis. DESIGN: Retrospective, interventional, noncomparative cohort study. PARTICIPANTS: Eighty-eight patients from a single-center private practice. METHODS: Patients with chronic, recalcitrant uveitis treated with infliximab (Remicade; Janssen Biotech, Inc., Titusville, NJ) were identified through an electronic medical record database...
January 2014: Ophthalmology
https://www.readbyqxmd.com/read/20506089/-swiss-registry-for-tnf-alpha-blockers-in-children-and-adolescents-with-rheumatological-diseases
#3
M J Sauvain, S B Schalm, G Bérthet, D Bolz, E Cannizzaro, M Hofer, D Kaiser, R K Saurenmann, I B Bolt
We created a registry to evaluate long term outcome, efficacy and adverse events for children treated wit TNF-alpha inhibitors in Switzerland. 106 patients (68 female/38 male) were included. 61 patients were treated with Etanercept (Enbrel) and 45 with Infliximab (Remicade). Concomitant treatment at baseline included corticosteroids in 26% and Methotrexate in 75% of the patients. Subjective disease activity three months after initiation of TNF-alpha was better in 81%, worse in 4% and stable in 15% of the patients...
May 26, 2010: Praxis
https://www.readbyqxmd.com/read/19906069/infliximab-for-the-treatment-of-psoriasis-in-greece-4-years-of-clinical-experience-at-a-single-centre
#4
C Antoniou, I Stefanaki, A Stratigos, E Moustou, T Vergou, P Stavropoulos, G Avgerinou, D Rigopoulos, A D Katsambas
BACKGROUND: Infliximab, a chimeric monoclonal antibody, has been shown to be effective for moderate to severe psoriasis. Clinical experience with long-term infliximab therapy for psoriasis is accumulating, and it is therefore important to share our experience with its use in real-life clinical practice. OBJECTIVES: To report our experience with infliximab (Remicade; Schering Plough, Kenilworth, NJ, U.S.A.) for the treatment of moderate to severe plaque psoriasis (and/or arthritis) from a single clinic in Greece...
May 2010: British Journal of Dermatology
https://www.readbyqxmd.com/read/18402168/-treatment-of-chronic-inflammatory-bowel-diseases
#5
REVIEW
Marc Lémann
The same drugs are used to treat hemorrhagic rectocolitis (HRC) and Crohn's disease (CD), although the aims are very different. Aminosalicylates are highly beneficial in HRC but virtually ineffective in CD, a disease in which immunosuppressants are more useful. Aminosalicylates exert their antiinflammatory effect directly on the lesions. Various oral and rectal preparations have been developed in order to deliver the active molecule to the intestinal target segment. These drugs are now known to act by stimulating the nuclear receptor PPAR-gamma, and this knowledge should help with the development of new agents...
June 2007: Bulletin de L'Académie Nationale de Médecine
https://www.readbyqxmd.com/read/18270925/-drug-induced-alveolitis-associated-with-infliximab-azathioprine-therapy
#6
K El-Hag, H-G Dercken, R Prenzel, E Hölzle
BACKGROUND: TNF-alpha is known to play a decisive role as a pro-inflammatory cytokine in several autoimmune conditions. Its neutralisation by TNF-alpha antagonists such as infliximab (Remicade), a chimeric monoclonal anti-TNF-alpha antibody, may be beneficial in patients with active disease. These anticytokine drugs have been approved and are being increasingly used in the therapy of rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriatic arthropathy and generalised psoriasis after established treatments have failed...
April 2008: Pneumologie
https://www.readbyqxmd.com/read/18189197/the-cost-effectiveness-of-infliximab-in-the-treatment-of-ankylosing-spondylitis-in-spain-comparison-of-clinical-trial-and-clinical-practice-data
#7
MULTICENTER STUDY
G Kobelt, P Sobocki, J Mulero, J Gratacos, E Collantes-Estevez, J Braun
OBJECTIVE: To estimate the cost-effectiveness of treating ankylosing spondylitis (AS) with infliximab (Remicade) in Spain for up to 40 years. METHODS: A previously published disease model was adapted to the Spanish setting using resource consumption from a cross-sectional burden of an illness study in 601 patients in Spain. Cost-effectiveness estimates were based on a placebo-controlled clinical trial as well as an open clinical study in Spain. In the model, patients with insufficient response to treatment at 12 weeks [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <4 or > or =50% reduction] discontinue treatment...
January 2008: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/16583476/the-cost-effectiveness-of-infliximab-remicade-in-the-treatment-of-ankylosing-spondylitis-in-canada
#8
Gisela Kobelt, Patrik Andlin-Sobocki, Walter P Maksymowych
OBJECTIVE: To estimate the cost-effectiveness of the treatment of ankylosing spondylitis (AS) with infliximab (Remicade) in Canada over the long term, with both international and Canadian treatment regimens. METHODS: A previously published disease model based on functional capacity and disease activity was adapted to the Canadian setting. Current resource consumption from a cross-sectional bottom-up burden-of-illness study in 545 patients at different levels of severity of AS in 4 Canadian provinces was incorporated into the model...
April 2006: Journal of Rheumatology
https://www.readbyqxmd.com/read/16573354/spotlight-on-infliximab-in-crohn-disease-and-rheumatoid-arthritis
#9
M Asif A Siddiqui, Lesley J Scott
Infliximab (Remicade) is a chimeric monoclonal antibody against tumor necrosis factor (TNF)-alpha that has shown efficacy in Crohn disease and rheumatoid arthritis with a disease-modifying activity and rapid onset of action. It is administered intravenously, generally in a schedule with initial infusions at 0, 2, and 6 weeks, followed by administration once every 8 weeks. Infliximab is effective in the treatment of patients with moderately to severely active Crohn disease with an inadequate response to other treatment options or those with fistulizing disease...
2006: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/16327716/-etanercept
#10
REVIEW
A Sparsa
Etanercept (Enbrel, Wyeth Pharmaceuticals) is a fusion protein composed of a soluble TNF alpha receptor issued from bio-technology. It is a member of TNF alpha's family with two others marked infliximab (Remicade, Scheringh Plough Laboratory), chimeric monoclonal antibody (25 p. 100 mouse) and adalimumab (Humira, Abbott France Laboratory), humanized monoclonal antibody (100 p. 100 human). In United States, etanercept is approved by Food and Drug Administration, since 1998, to treat rheumatoid arthritis showing an inadequate response to prior therapy with other disease-modifying antirheumatic drugs (DMARDS)...
November 2005: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/16225377/infliximab-a-review-of-its-use-in-crohn-s-disease-and-rheumatoid-arthritis
#11
REVIEW
M Asif A Siddiqui, Lesley J Scott
Infliximab (Remicade) is a chimeric monoclonal antibody against tumour necrosis factor (TNF)-alpha that has shown efficacy in Crohn's disease and rheumatoid arthritis with a disease-modifying activity and rapid onset of action. It is administered intravenously, generally in a schedule with initial infusions at 0, 2 and 6 weeks, followed by administration once every 8 weeks. Infliximab is effective in the treatment of patients with moderately to severely active Crohn's disease with an inadequate response to other treatment options or those with fistulising disease...
2005: Drugs
https://www.readbyqxmd.com/read/16050786/infliximab-for-the-treatment-of-ankylosing-spondylitis
#12
REVIEW
M Rudwaleit, J Sieper
Ankylosing spondylitis (AS) had previously been considered as a chronic disease with little therapeutic options. Non-steroidal anti-inflammatory drugs (NSAIDs) and regular physiotherapy were the only treatment modalities available for patients with AS. The introduction of biologics into clinical practice has substantially broadened the therapeutic armamentarium in AS patients who are refractory to NSAIDs. Remicade (infliximab; Centocor, Inc., USA), a chimeric monoclonal antibody, targets TNF-alpha, and by inhibition of this proinflammatory cytokine, exerts strong clinical improvement of signs and symptoms of AS...
August 2005: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/15226514/the-burden-of-ankylosing-spondylitis-and-the-cost-effectiveness-of-treatment-with-infliximab-remicade
#13
RANDOMIZED CONTROLLED TRIAL
G Kobelt, P Andlin-Sobocki, S Brophy, L Jönsson, A Calin, J Braun
OBJECTIVES: In the past, treatment options for ankylosing spondylitis (AS) have been limited, and the introduction of new treatments such as infliximab will have a noticeable impact on health-care budgets. The objective of this study was therefore to assess the current burden of the disease and estimate the cost-effectiveness of infliximab treatments. METHODS: A cross-sectional retrospective observational study of resource consumption and utility related to disease severity was performed in patients who had participated in a population survey between 1992 and 1994 at the University of Bath and patients regularly followed at the Royal National Hospital for Rheumatic Diseases in Bath for up to 9 years...
September 2004: Rheumatology
https://www.readbyqxmd.com/read/15187239/biological-therapies-in-the-spondyloarthritides-the-current-state
#14
REVIEW
J Braun, J Sieper
Therapeutic options for patients suffering from the more severe spondyloarthritides (SpA) have been rather limited in the last decades. Evidence is now accumulating that anti-tumour necrosis factor (TNF) therapy is highly effective in SpA, especially in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Based on the data recently published concerning more than 1000 patients with AS and PsA, this treatment seems to be even more effective than in rheumatoid arthritis (RA). The anti-TNFalpha agents currently available, infliximab (Remicade), etanercept (Enbrel) and adalimumab (Humira), are approved for the treatment of RA in the USA and Europe...
September 2004: Rheumatology
https://www.readbyqxmd.com/read/12831346/novel-approaches-in-the-treatment-of-ankylosing-spondylitis-and-other-spondyloarthritides
#15
REVIEW
Juergen Braun, Désirée van der Heijde
The therapeutic options for patients suffering from severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. There is now accumulating evidence that anti-TNF therapy is highly effective in SpA, especially in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Based on the data recently published on what is now several hundred AS and PsA patients, this treatment seems to be even more effective than the same therapy in rheumatoid arthritis (RA). The anti-TNF-alpha agents currently available, infliximab (Remicade); Centocor), etanercept (Enbrel); Amgen) and adalimumab (Humira; Abbott), are approved for the treatment of RA in the US; infliximab and etanercept are approved in Europe...
July 2003: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/12819466/biologic-therapies-in-the-spondyloarthritis-new-opportunities-new-challenges
#16
REVIEW
Juergen Braun, Jan Brandt, Joachim Listing, Martin Rudwaleit, Joachim Sieper
Therapeutic options for patients suffering from the more severe forms of spondyloarthritis have been rather limited in the last decades. There is now accumulating evidence that antitumor necrosis factor therapy is highly effective in spondyloarthritis, especially in ankylosing spondylitis and psoriatic arthritis. Based on the data recently published on more than 500 patients with ankylosing spondylitis and psoriatic arthritis, this treatment seems to be even more effective than in rheumatoid arthritis. The antitumor necrosis factor-alpha agents currently available, infliximab (Remicade), etanercept (Enbrel), and adalimumab (Humira), are approved for the treatment of rheumatoid arthritis in the United States and partly in Europe...
July 2003: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/12717087/a-prospective-study-of-the-efficacy-and-tolerance-of-a-chimeric-antibody-to-tumor-necrosis-factors-remicade-in-severe-pediatric-crohn-disease
#17
Jean-Pierre Cezard, Nizar Nouaili, Cécile Talbotec, Jean-Pierre Hugot, Jean-Gérard Gobert, Jacques Schmitz, Jean-François Mougenot, Corinne Alberti, Olivier Goulet
OBJECTIVES: To evaluate the efficacy and toxicity of infliximab in children with severe Crohn disease (CD), the authors prospectively monitored 21 children aged 15 +/- 2 years with severe CD who they treated with infliximab (5 mg/kg) on days 0, 15, and 45. One patient received only one injection. Eighteen patients were corticosteroid dependent, and 6 were receiving parenteral nutrition. Three patients were corticoid resistant (1 mg/kg/d >15 days). Sixteen had perianal disease. RESULTS: The Harvey-Bradshaw index (HB) decreased from 8 +/- 3 on day 0 to 1 +/- 2 on day 45 (P = 0...
May 2003: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/12406431/therapy-for-ankylosing-spondylitis-new-treatment-modalities
#18
REVIEW
J Braun, Maxime Breban, Walter P Maksymowych
The therapeutic options for patients suffering from the more severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. There is now accumulating evidence that anti-tumour necrosis factor (anti-TNF) therapy is highly effective in SpA, especially in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Based on the data recently published on more than 200 AS patients, and more than 100 PsA patients, this treatment seems to be even more effective than it is in rheumatoid arthritis (RA)...
September 2002: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/12223105/therapy-of-ankylosing-spondylitis-and-other-spondyloarthritides-established-medical-treatment-anti-tnf-alpha-therapy-and-other-novel-approaches
#19
REVIEW
Juergen Braun, Joachim Sieper
Therapeutic options for patients with more severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. There is accumulating evidence that anti-tumor-necrosis-factor (anti-TNF) therapy is highly effective in SpA, especially in ankylosing spondylitis and psoriatic arthritis. The major anti-TNF-alpha agents currently available, infliximab (Remicade(R)) and etanercept (Enbrel(R)), are approved for the treatment of rheumatoid arthritis (RA) in many countries. In ankylosing spondylitis there is an unmet medical need, since there are almost no disease-modifying antirheumatic drugs (DMARDs) available for severely affected patients, especially those with spinal manifestations...
2002: Arthritis Research
https://www.readbyqxmd.com/read/11847424/engineered-antibodies-take-center-stage
#20
REVIEW
J S Huston, A J George
The start of the post-genomic era provides a useful juncture for reflection on the state of antibody engineering, which will be a critical technology for relating function and pathology to genomic sequence in biology and medicine. The phenomenal progress in deciphering the human genome has given significant impetus to the application of engineered antibodies in proteomics. Thus, advances in phage display antibody libraries can now help to define novel gene function and the measurement of abnormal protein expression in pathological states...
2001: Human Antibodies
keyword
keyword
170862
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"